{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.0","upperLimit":"62.5","value":"56.5"},{"groupId":"OG001","lowerLimit":"41.3","upperLimit":"53.7","value":"47.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"264"},{"groupId":"OG001","value":"266"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization until death due to any cause. The OS36 was defined as the Kaplan-Meier estimate of OS at 36 months after randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received durvalumab monotherapy (1500 mg for participants \\>30 kg in weight and a weight-based dosing equivalent to 20 mg/kg for participants \\<=30 kg in weight) via IV infusion once q4w, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"OG000","title":"Durvalumab"},{"description":"Participants received matching placebo via IV infusion once q4w for 4 doses/cycles each, until clinical/RECIST 1.1-defined radiological progression, intolerable toxicity, or for a maximum of 24 months, whichever occurred first.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Month 36","title":"Durvalumab Versus Placebo: Percentage of Participants Alive at 36 Months From Randomization (OS36)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}